Gainers
- Windtree Therapeutics Inc WINT shares rose 65.3% to $0.28 in pre-market trading. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous Formulation For The Treatment Of Acute Heart Failure."
- Cyren Ltd CYRN rose 50.2% to $0.62 in pre-market trading after the company reported non-binding LOI to sell Iceland-based anti-malware business assets.
- Sorrento Therapeutics Inc SRNE rose 44.4% to $0.56 in pre-market trading after the company received court approval for $75 million financing in Chapter 11 case.
- Wag! Group Co PET rose 21.7% to $2.80 in pre-market trading after the company posted better-than-expected Q4 earnings.
- Greenlane Holdings Inc GNLN rose 21.7% to $0.46 in pre-market trading after the company said it has reduced its current loan facility by over 40% to approximately $8.5 million, while also receiving more than $4.8 million from the sale of its Employee Retention Credit..
- Hoth Therapeutics Inc HOTH shares rose 14.3% to $2.96 in pre-market trading after dropping over 9% on Tuesday. Hoth Therapeutics recently entered into a service agreement with Shareholder Intelligence Services to investigate and report on potential illegal naked short selling activities of its stock.
- Mind Medicine (MindMed) Inc MNMD rose 10.7% to $4.20 in pre-market trading after dropping around 4% on Tuesday.
- Vinco Ventures Inc BBIG shares rose 9.8% to $0.58 in pre-market trading after dropping 8% on Tuesday.
- 1life Healthcare Inc ONEM rose 8.6% to $17.88 in pre-market trading following reports the Federal Trade Commission won't challenge Amazon.com's takeover bid. 1Life Healthcare also posted a Q4 loss of $0.49 per share.
- Palo Alto Networks Inc PANW rose 8.2% to $180.62 in pre-market trading after the company reported better-than-expected Q2 results and issued strong guidance.
Losers
- Ambrx Biopharma Inc - ADR AMAM shares fell 17.1% to $3.77 in pre-market trading after jumping 45% on Tuesday. Ambrx Biopharma recently announced initial data from its ongoing Phase 1 APEX-01 trial of ARX517, Ambrx's proprietary anti-PSMA ADC, in prostate cancer patients.
- Ziprecruiter Inc ZIP shares dropped 15.1% to $19.73 in pre-market trading after the company reported a 4% year-over-year decrease in Q4 revenue.
- CoStar Group Inc CSGP fell 14.7% to $64.86 in pre-market trading after the company issued weak Q1 guidance.
- Esports Entertainment Group Inc GMBL fell 13.7% to $5.11 in pre-market trading. Esports Entertainment Group announced a 1-for-100 reverse stock split.
- Harbor Custom Development Inc HCDI fell 13.7% to $0.44 in pre-market. Harbor Custom Development, on Tuesday, announced it has contracted to sell the Mills Crossing townhomes in Bremerton, WA for $14,250,000 to Kitsap Community Resources.
- JE Cleantech Holdings Ltd JCSE fell 11.2% to $0.67 in pre-market trading after dropping over 5% on Tuesday.
- eFFECTOR Therapeutics Inc EFTR fell 10.5% to $0.45 in pre-market trading after dropping 20% on Tuesday. eFFECTOR Therapeutics announced top-line results from its Phase 1b clinical trial of zotatifin for COVID-19 infection.
- Nutex Health Inc NUTX fell 10.4% to $1.19 in pre-market trading after declining around 4% on Tuesday.
- Kuke Music Holding Ltd - ADR KUKE fell 9.4% to $0.97 in pre-market trading after jumping around 43% on Tuesday.
- Medifast Inc MED shares fell 9% to $96.00 in pre-market trading after the company issued weak forecast for the current quarter.
Now Read This: NVIDIA Likely To Report Lower Quarterly Earnings, Here's A Look At Recent Price Target Changes By The Most Accurate Analysts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPenny StocksSmall CapPre-Market OutlookMarketsMoversTrading IdeasPremarket MoversTop Gainers
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in